MarketCapExport financials
Theravance Biopharma (TBPH)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Theravance Biopharma Financial Ratios 2025-2011 | TBPH
Brief overview of Theravance Biopharma's valuation multiples
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The valuation comparison uses P/S 16.17x (median 29.56x), P/B 1.53x (median 1.36x). On average, this basket is 16.4% below its own five-year medians. The market values the business at a discount to recent history.
End-period return metrics are ROE 35.7%, ROA 21.8%, ROCE 6.7%. Current resource returns are convincing and help explain a higher market valuation.
PEG is 0.37x. Price is low relative to embedded growth, though the ratio depends heavily on forecast quality.
Overall picture
Theravance Biopharma's high-quality returns come with historically restrained multiples. Price appears more cautious than current business efficiency.
Annual Financial Ratios Theravance Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
7.0 | -8.3 | -9.4 | -72.8 | -19.8 | -4.2 | -6.6 | -6.3 | -5.0 | -6.6 | -3.1 | -2.2 | - | - | - |
P/S |
16.2 | 24.9 | 29.6 | 51.5 | 42.3 | 16.2 | 21.2 | 22.5 | 91.8 | 26.0 | 13.3 | 44.1 | - | - | - |
EPS |
1.2 | -0.3 | -0.2 | -0.1 | -0.4 | -4.5 | -4.2 | -4.0 | -5.5 | -4.3 | -5.3 | -7.5 | -4.9 | -0.3 | - |
EV (Enterprise Value) |
574 M | 429 M | 480 M | 456 M | 543 M | 1.08 B | 2.13 B | 1.59 B | 1.65 B | 1.21 B | 505 M | 474 M | 42.2 M | - | - |
EBITDA per Share |
0.43 | -0.16 | -0.08 | -0.2 | -0.76 | -4.72 | -4.41 | -4.37 | -5.04 | -3.97 | -5.24 | -7.22 | - | - | - |
EV/EBITDA |
26.7 | -56.5 | -110.5 | -30.8 | -2.1 | -3.8 | -8.0 | -6.1 | -5.9 | -6.4 | -2.5 | -1.9 | - | - | - |
PEG |
-0.07 | 0.37 | 0.22 | 2.23 | 1.59 | 8.27 | 1.02 | -0.24 | 0.18 | -0.33 | -0.11 | 0.04 | - | - | - |
P/B |
1.5 | 1.3 | 1.4 | 1.2 | 1.7 | 2.5 | -6.9 | -26.3 | 12.3 | 3.6 | 2.3 | 1.8 | - | - | - |
P/CF |
3.1 | -40.5 | -19.2 | -4.0 | -3.0 | -4.6 | -6.4 | -11.3 | -6.9 | -12.5 | -3.3 | -2.9 | - | - | - |
ROE % |
35.69 | -32.14 | -25.91 | -2.35 | 9.46 | 91.53 | 105.64 | 417.77 | -247.79 | -54.44 | -74.97 | -81.80 | - | - | - |
ROA % |
21.81 | -15.93 | -14.45 | -1.71 | -8.55 | -59.27 | -57.84 | -38.47 | -64.66 | -29.83 | -60.72 | -70.18 | - | - | - |
ROCE % |
6.74 | -5.24 | -2.93 | -3.95 | 16.59 | 97.98 | -84.78 | -51.71 | -70.77 | -30.59 | -72.57 | -78.42 | - | - | - |
Current Ratio |
- | - | - | - | - | - | 3.0 | 5.4 | 6.1 | 10.7 | 4.8 | 6.7 | - | - | - |
DSO |
- | - | - | - | - | - | 251.4 | 64.5 | 222.1 | 72.9 | 321.9 | 66.5 | - | - | - |
DIO |
- | - | - | - | - | - | - | - | 1018.7 | 1541.2 | 784.2 | 1128.5 | - | - | - |
DPO |
- | - | - | - | - | - | - | 4608.7 | 358.6 | 218.6 | 1473.8 | 892.4 | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | 64.5 | 1240.8 | 1614.2 | 1106.1 | 1194.9 | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | -4544.2 | 882.2 | 1395.6 | -367.7 | 302.6 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Theravance Biopharma
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.09 | -0.1 | -0.24 | 0.07 | 1.09 | -0.27 | - | -0.26 | -0.34 | -0.24 | - | -0.17 | -0.28 | -0.35 | - | 12.14 | -0.11 | -0.34 | -0.43 | -0.48 | -0.8 | -1.24 | -0.92 | -1.16 | -1 | -1.4 | -1.17 | -1.05 | -0.72 | -1.32 | -0.92 | -1.1 | -0.76 | -1.22 | -1.64 | -1.27 | -1.27 | -1.27 | -1.36 | -0.73 | -1.06 | -1.1 | -1.23 | -1.4 | -1.42 | -1.29 | -2.02 | -1.72 | -1.83 | -1.89 | -1.39 | -1.29 | -1.23 | -1.01 | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.05 | -0.18 | - | - | - | -0.29 | - | - | - | - | - | - | - | - | - | -0.19 | -0.3 | -0.49 | -0.75 | -0.73 | -0.98 | -1.3 | -1.19 | -1.21 | -1.14 | -1.21 | -1.24 | -1.15 | -0.75 | -1.3 | -1.12 | -1.13 | -0.89 | -1.2 | -1.46 | -1.03 | -1.21 | -1.12 | -1.09 | -0.68 | -1.04 | -1.07 | -1.47 | -1.21 | -1.3 | -1.12 | -2.04 | -1.5 | -1.74 | -1.87 | - | -1.23 | -1.18 | - | - | - | - | - | - | - | - | - |
ROE % |
25.62 | 18.77 | 12.28 | 10.92 | 0.83 | -29.25 | -21.07 | -24.70 | -23.45 | -20.87 | -15.18 | 175.55 | 181.53 | 194.50 | 200.46 | 209.92 | 30.10 | 45.20 | 59.17 | 68.94 | 82.28 | 85.53 | 91.53 | 101.60 | 103.46 | 100.55 | 105.64 | 173.61 | 262.71 | 324.03 | 417.77 | 245.02 | 71.75 | -64.92 | -247.79 | -191.55 | -143.19 | -99.12 | -54.44 | -53.66 | -63.43 | -69.53 | -74.97 | -78.72 | -78.06 | -78.56 | -81.80 | 199.16 | 459.10 | 707.85 | 917.43 | 241.14 | 228.66 | 188.87 | - | - | - | - | - | - | - | - |
ROA % |
7.83 | 9.40 | 6.50 | 6.22 | 0.79 | -15.22 | -11.27 | -13.44 | -13.37 | -12.91 | -9.77 | 110.29 | 110.18 | 106.38 | 110.49 | 101.94 | -26.88 | -36.82 | -50.76 | -54.67 | -61.61 | -62.81 | -59.27 | -62.86 | -61.45 | -57.79 | -57.84 | -50.75 | -47.06 | -44.61 | -38.47 | -49.20 | -53.75 | -61.48 | -64.66 | -55.50 | -45.66 | -38.03 | -29.83 | -34.23 | -44.68 | -53.16 | -60.72 | -64.82 | -65.19 | -66.56 | -70.18 | -226.22 | -373.24 | -510.72 | -620.74 | -163.16 | -154.71 | -127.79 | - | - | - | - | - | - | - | - |
ROCE % |
-12.85 | -12.51 | -17.94 | -18.52 | -23.85 | -28.11 | -19.42 | -22.98 | -22.89 | -21.51 | -16.04 | -18.99 | -8.83 | 7.52 | 14.24 | 30.83 | 50.35 | 65.09 | 76.98 | 85.57 | 94.23 | 96.64 | 98.03 | 104.37 | 108.28 | 103.49 | 112.54 | 202.40 | 294.32 | 369.76 | 462.79 | 272.67 | 102.13 | -48.82 | -225.84 | -173.62 | -133.69 | -90.71 | -51.53 | -57.96 | -66.13 | -71.20 | -74.84 | -74.58 | -74.13 | -75.06 | -80.24 | 201.21 | 459.62 | 707.85 | 917.43 | 241.14 | 228.66 | 188.87 | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.7 | 0.4 | 6.3 | 3.6 | 4.4 | 2.4 | 15.8 | 45.5 | 48.1 | 58.6 | 42.9 | 10.4 | 3.1 | 10.8 | 6.4 | 45.0 | 16.4 | 24.6 | 4.9 | 18.4 | 4.2 | 8.9 | 23.6 | 103.8 | 756.6 | 3631.8 | 412.7 | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.7 | 0.4 | 6.3 | 3.6 | 4.4 | 2.4 | 15.8 | 45.5 | 48.1 | 58.6 | 42.9 | 10.4 | 3.1 | 10.8 | 6.4 | 45.0 | 16.4 | 24.6 | 4.9 | 18.4 | 4.2 | 8.9 | 23.6 | 103.8 | 756.6 | 3631.8 | 412.7 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | 0.7 | 0.4 | 6.3 | 3.6 | 4.4 | 2.4 | 15.8 | 45.5 | 48.1 | 58.6 | 42.9 | 10.4 | 3.1 | 10.8 | 6.4 | 45.0 | 16.4 | 24.6 | 4.9 | 18.4 | 4.2 | 8.9 | 23.6 | 103.8 | 756.6 | 3631.8 | 412.7 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Theravance Biopharma, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Germany
Israel
Britain
Canada
Russia
Schweiz
China